Citations

Showing 10 of 108152 citations.

Immediate and delayed coronary angiography did not differ for survival after OHCA without STEMI
Vallabhajosyula, Saraschandra , Bell, Malcolm R. , Vallabhajosyula, Saraschandra

Mayo Clinic

Annals of Internal Medicine | July 15, 2019 | Volume: 171 | Issue: 2 | Pages: JC4

10.7326/acpj201907160-004 | PMID 31307065 Get It

Reply
Sharma, Mayank , Simonettos, Douglas A.

Mayo Clinic

Hepatology | July 15, 2019 | Volume: 70 | Issue: 5 | Pages: 1877-1877

10.1002/hep.30855 | PMID 31306502 Get It

To Screen or Not to Screen, That Is the Question
Ommen, Steve R. , Ommen, Steve, Mital, Seema

Mayo Clinic

Circulation | July 15, 2019 | Volume: 140 | Issue: 3 | Pages: 193-195

10.1161/circulationaha.119.041021 | PMID 31306063 Get It

Use of Twitter to Promote Awareness of Familial Hypercholesterolemia
Bangash, Hana , Khan, Fiza , He, Baosheng, Arce, Makala, Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | July 15, 2019 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/circgen.119.002550 | PMID 31306057 Get It

Prospective study on embolization of intracranial aneurysms with the pipeline device: the PREMIER study 1 year results
Kallmes, David F. , Nelson, Peter Kim , Siddiqui, Adnan H. , Szikora, István , Zaidat, Osama O. , Colby, Geoffrey P. , Schirmer, Clemens M. , Hellinger, Frank R, Given, Curtis A., Tóth, Gábor , Priest, Ryan , Kan, Peter , Frei, Don , Aagaard‐Kienitz, Beverly , Díaz, Orlando , Malek, Adel M. , Cawley, C. Michael , Puri, Ajit S , Zaidat, Osama O , Colby, Geoffrey P , Mokin, Maxim , Taussky, Philipp , Toth, Gabor , Fraser, Justin F , Fiorella, David , Siddiqui, Adnan H , Szikora, Istvan , Schirmer, Clemens M , Hanel, Ricardó A. , Lopes, Demetrius K. , Jabbour, Pascal , Mendes Pereira, Vitor , Bettegowda, Chetan , Krings, Timo , Chen, Michael , Fiorella, David

Mayo Clinic

Journal of NeuroInterventional Surgery | July 15, 2019 | Volume: 12 | Issue: 1 | Pages: 62-66

10.1136/neurintsurg-2019-015091 | PMID 31308197 Get It

Background Preliminary clinical studies on the safety and efficacy of the pipeline embolization device (PED) for the treatment of small/medium aneurysms have demonstrated high occlusion rates with low complications. Objective To evaluate the safety and effectiveness of the PED for treatment of wide necked small and medium intracranial aneurysms. Methods PREMIER is a prospective, multicenter, single arm trial. Patients were treated with the PED for unruptured wide necked aneurysms, measuring ≤12 mm along the internal carotid artery or vertebral artery, between July 2014 and November 2015. At 1 year post-procedure, the primary effectiveness endpoint was complete occlusion (Raymond grade 1) without major parent vessel stenosis (≤50%) or retreatment, and the primary safety endpoint was major stroke in the territory supplied by the treated artery or neurologic death. Results A total of 141 patients were treated with PEDs (mean age 54.6±11.3 years, 87.9% (124/141) women). Mean aneurysm size was 5.0±1.92 mm, and 84.4% (119/141) measured <7 mm. PED placement was successful in 99.3% (140/141) of patients. Mean number of PEDs implanted per patient was 1.1±0.26; a single PED was used in 92.9% (131/141) of patients. At 1 year, 97.9% (138/141) of patients underwent follow-up angiography with 76.8% (106/138) of patients having met the study’s primary effectiveness endpoint. The combined major morbidity and mortality rate was 2.1% (3/140). Conclusions Treatment of wide necked small/medium aneurysms with the PED results in high rates of complete occlusion without significant parent vessel stenosis and low rates of permanent neurologic complications. Trial registration NCT02186561 .
Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies
Collins, Michael P. , Dyck, P. James B. , Hadden, Robert D. M.

Mayo Clinic

Current Opinion in Neurology | July 15, 2019 | Volume: 32 | Issue: 5 | Pages: 684-695

10.1097/wco.0000000000000727 | PMID 31313704 Get It

Purpose of review Single-organ vasculitis of the peripheral nervous system (PNS) is often designated nonsystemic vasculitic neuropathy (NSVN). Several variants or subtypes have been distinguished, including migratory sensory neuropathy, postsurgical inflammatory neuropathy, diabetic radiculoplexus neuropathies, skin-nerve vasculitides, and, arguably, neuralgic amyotrophy. NSVN often presents as nondiabetic lumbosacral radiculoplexus neuropathy (LRPN). This review updates classification, clinical features, epidemiology, and imaging of these disorders. Recent findings A recent study showed the annual incidence of LRPN in Olmstead County, Minnesota to be 4.16/100 000:2.79/100 000 diabetic and 1.27/100 000 nondiabetic. This study was the first to determine the incidence or prevalence of any vasculitic neuropathy. In NSVN, ultrasonography shows multifocal enlargement of proximal and distal nerves. In neuralgic amyotrophy, MRI and ultrasound reveal multifocal enlargements and focal constrictions in nerves derived from the brachial plexus. Histopathology of these chronic lesions shows inflammation and rare vasculitis. Diffusion tensor imaging of tibial nerves in NSVN revealed decreased fractional anisotropy in one study. Summary Single-organ PNS vasculitides are the most common inflammatory neuropathies. Neuralgic amyotrophy might result from PNS vasculitis, but further study is necessary. The usefulness of focal nerve enlargements or constrictions in understanding pathological mechanisms, directing biopsies, and monitoring disease activity in NSVN should be further investigated.
N-Glycosylation influences human corticosteroid-binding globulin measurements
Hill, Lesley A. , Sumer‐Bayraktar, Zeynep , Thaysen‐Andersen, Morten , Hammond, Geoffrey L. , Lewis, John G. , Morava, Éva

Mayo Clinic

Endocrine Connections | July 15, 2019 | Volume: 8 | Issue: 8 | Pages: 1136-1148

10.1530/ec-19-0242 | PMID 31307013 Get It

Objective Discrepancies in ELISA measurements of human corticosteroid-binding globulin (CBG) using detection monoclonal antibodies that recognize an epitope (9G12) within its reactive center loop (RCL), versus an epitope (12G2) in a different location, have suggested that CBG with a proteolytically cleaved RCL exists in blood samples. We have previously been unable to verify this biochemically, and sought to determine if N -glycosylation differences account for discrepancies in ELISA measurements of CBG. Methods and subjects Molecular biological, biochemical and glycopeptide analyses were used to examine how N -glycosylation at specific sites, including at N347 within the RCL, affect CBG ELISA or steroid-binding capacity assay (BCA) measurements. Plasma from patients with congenital disorders of glycosylation (CDG) was also examined in these assays as examples of N -glycosylation defects. Results We demonstrate that an N -glycan at N347 within the CBG RCL limits the 9G12 antibody from recognizing its epitope, whereas the 12G2 antibody reactivity is unaffected, thereby contributing to discrepancies in ELISA measurements using these two antibodies. Qualitative differences in N -glycosylation at N238 also negatively affect the steroid-binding of CBG in the absence of an N -glycan at N347 caused by a T349A substitution. Desialylation increased both ELISA measurements relative to BCA values. Similarly, plasma CBG levels in both ELISAs were much higher than BCA values in several CDG patients. Conclusions Plasma CBG measurements are influenced by variations in N -glycosylation. This is important given the increasing number of CDG defects identified recently and because N -glycosylation abnormalities are common in patients with metabolic and liver diseases.
Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework
Jack, Clifford R. , Therneau, Terry M. , Weigand, Stephen D. , Wiste, Heather J. , Vemuri, Prashanthi , Lowe, Val J. , Roberts, Rosebud O., Graff‐Radford, Jonathan , Gunter, Jeffrey L. , Senjem, Matthew L. , Rocca, Walter A. , Petersen, Ronald C. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Jones, David T. , Schwarz, Christopher G.

Mayo Clinic

JAMA Neurology | July 15, 2019 | Volume: 76 | Issue: 10 | Pages: 1174

10.1001/jamaneurol.2019.1971 | PMID 31305929 Get It

Pregnancy History Is Imperative for Cardiovascular Risk Assessment in Black Women
Tweet, Marysia S.

Mayo Clinic

Circulation: Cardiovascular Imaging | July 15, 2019 | Volume: 12 | Issue: 7 | Pages: No page available

10.1161/circimaging.119.009439 | PMID 31303029 Get It

Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing
Majumder, Shounak , Yab, Tracy C. , Dukek, Brian A. , Cao, Xiaoming , Wu, Chung Wah, Aslanian, Harry R., Castillo, Carlos Fernández-del, Doyle, Leona A. , Farrell, James J. , Fisher, William E., Lee, Yvonne N., Park, Walter G. , Rodrigues, Clifton, Salem, Ronald R. , Simeone, Diane M. , Urs, Sumithra, Buren, George Van , Smyrk, Thomas C. , Allawi, Hatim T. , Lidgard, Graham P. , Chari, Suresh T. , Kendrick, Michael L. , Topazian, Mark , Ahlquist, David A. , Berger, Calise K. , Foote, Patrick H. , Mahoney, Douglas W. , Raimondo, Massimo , Kisiel, John B. , Majumder, Shounak , Taylor, William R. , Lee, Linda , Rodrigues, Clifton, Gould Rothberg, Bonnie E , Chari, Suresh T

Mayo Clinic

American Journal of Gastroenterology | July 15, 2019 | Volume: 114 | Issue: 9 | Pages: 1539-1549

10.14309/ajg.0000000000000284 | PMID 31306149 Get It

OBJECTIVES: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs ( TBX15 , BMP3 ) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86–0.99), 0.71 (0.57–0.85), and 0.72 (0.60–0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77–0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.